Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi(Center for Cancer Research), Nirali N. Shah(National Institutes of Health), Terry J. Fry(University of Colorado Anschutz Medical Campus), Julie D. Zimbelman, Bonnie Yates(National Institutes of Health), Cindy Delbrook(National Institutes of Health), Roger Giller(Center for Cancer and Blood Disorders), Ira L. Kraft(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Daniel W. Lee(University of Virginia Cancer Center), Elaine S. Jaffe(National Cancer Institute), Jack F. Shern(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Constance M. Yuan(National Cancer Institute)
Cited by 171
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k